Is Amyloidosis Hereditary? A Type-by-Type Genetic Risk Guide

The direct answer is that it depends on the type: amyloidosis is a family of disorders in which misfolded proteins form rigid fibrils and accumulate in tissues, and only some forms pass from parent to child. Hereditary transthyretin amyloidosis (ATTRv) is the inherited version, driven by a mutation in the TTR gene, while AL amyloidosis is acquired from faulty plasma cells and AA amyloidosis is driven by chronic inflammation, so neither runs in families in the usual sense.

This guide walks through how each type behaves genetically, what autosomal dominant inheritance looks like on a real pedigree, and the concrete steps worth taking next if a relative carries an inherited diagnosis.

Amyloidosis at a Glance and Why Genetics Matters

Amyloidosis describes a group of disorders where proteins misfold, stack into rigid fibrils, and accumulate in tissues where they don’t belong. Over time, those deposits stiffen heart walls, damage nerves, and disrupt kidneys, the gut, and other organs. Because the same word covers many diseases, asking whether amyloidosis is hereditary only makes sense once the specific protein behind the buildup is named.

Three forms come up most often in clinical practice: AL, AA, and ATTR. AL amyloidosis starts in the bone marrow when plasma cells produce misfolded antibody fragments. AA amyloidosis grows out of long-standing inflammatory conditions such as rheumatoid arthritis or chronic infections. ATTR amyloidosis comes from the liver-made transport protein transthyretin and splits into hereditary (ATTRv) and age-related wild-type (ATTRwt) versions. The first two are acquired; only the ATTR branch carries a heritable mutation.

• ▸AL amyloidosis: Acquired. Driven by abnormal plasma cells, not inherited gene variants.
• ▸AA amyloidosis: Acquired. Driven by chronic inflammation, not inherited gene variants.
• ▸ATTRv amyloidosis: Hereditary. Caused by a mutation in the TTR gene passed from parent to child.
• ▸ATTRwt amyloidosis: Age-related. No mutation involved; linked to aging-related protein instability.
• ▸Rare hereditary forms: Caused by mutations in genes such as APOA1, FGA, LYZ, and GSN.

Why the genetic question matters for your family: if a parent or sibling carries an inherited TTR mutation, your own risk changes, and so does the risk for your children. That single fact reshapes family screening, reproductive planning, and how quickly relatives should be evaluated for early heart or nerve symptoms.

Which Types of Amyloidosis Are Passed Down in Families

Hereditary transthyretin amyloidosis is the form that runs in families. It traces to the TTR gene on chromosome 18, which carries the instructions for transthyretin, a protein made mostly in the liver that ferries thyroid hormone and vitamin A through the blood. More than 130 different TTR mutations have been linked to disease, and the most common of them travels in an autosomal dominant pattern, meaning a single altered copy is enough to pass on risk.

ATTRv vs AL vs AA at a Glance

AL amyloidosis is the most common type in the United States, and despite fears some family members carry, it is not passed down from parent to child. AA amyloidosis behaves the same way: the protein involved (serum amyloid A) rises in response to long-standing inflammation, and the disease itself is not inherited. Wild-type ATTR, increasingly recognized in older men with thickened heart walls, also lacks a hereditary mutation; the protein simply becomes unstable with age.

Rare Hereditary Forms Worth Knowing

A handful of other genes can also produce hereditary amyloid disease, though each is far rarer than ATTRv. Mutations in APOA1 (apolipoprotein A1) affect the heart, liver, and sometimes the kidneys. FGA mutations cause fibrinogen amyloidosis, which typically damages the kidneys in older adults. LYZ mutations lead to lysozyme amyloidosis with slowly progressive kidney and GI involvement, and GSN mutations affect gelsolin, sometimes producing the lattice corneal dystrophy seen in certain Finnish and Japanese families. If a relative has been told their amyloidosis isn’t AL or AA but no specific gene has been named, one of these rarer forms may be the answer.

Rarer mutations are still inherited by the same autosomal-dominant rules, so understanding who carries the gene explains why families see such uneven patterns.

How Hereditary Amyloidosis Moves Through a Family

ATTRv follows autosomal dominant inheritance, which means every child of an affected parent has a 50% chance of inheriting the altered TTR copy. That number stays the same with every pregnancy and is identical whether the child is a son or a daughter. A common worry is that the disease “skipped a generation,” and what usually happened is variable penetrance: some carriers stay asymptomatic for decades or for life, while others develop problems in their 20s or 70s.

A Simple TTR Family Tree

Picture a parent who carries a TTR mutation. Out of four children, two on average inherit the altered gene. Those two may face very different futures: one develops neuropathy at 35, the other lives to 80 with no symptoms yet still carries the mutation. Below them, each grandchild faces the same 50% coin flip their parent did, regardless of how visibly ill the grandparent was.

The V30M variant (also called Val30Met or p.V50M depending on the naming convention) is the most common TTR variant worldwide, with regional concentrations in Portugal, Japan, and Sweden, where the disease was first formally described. Other variants, such as V122I (present in roughly 3–4% of individuals of West African ancestry in the U.S.), T60A, and I84S, appear more often in specific populations, and a few produce predominantly heart symptoms instead of nerve symptoms.

“Tip: If you only know that a relative “had amyloidosis,” ask which protein (TTR, light chain, or SAA) was involved and whether genetic testing was done. The answer reframes everyone else’s risk.

Symptoms, Age of Onset, and Why Carriers Can Look Fine for Years

The age when symptoms appear in hereditary ATTR depends heavily on the specific TTR variant, the family background, and even sex in some populations. Onset ranges from the early 20s (notably for V30M in Portugal and Japan) to the 60s or 70s (for variants such as V122I). Carriers of the same mutation can diverge by decades, and many live their entire lives without a single clear symptom, which is exactly what makes family communication so important.

Two Main Hereditary ATTR Presentations

Familial amyloid polyneuropathy (FAP) leads with progressive nerve damage: numbness or burning in the lower legs, autonomic symptoms such as dizziness on standing, erectile dysfunction, severe constipation or diarrhea, and unintentional weight loss. Familial amyloid cardiomyopathy (FAC) leads with heart involvement: thickened ventricular walls, stiffness that causes heart failure with preserved ejection fraction, and arrhythmias. Some variants cause a mixed picture, and bilateral carpal tunnel release surgery in an adult under 60 is now recognized as an early red flag for both ATTRwt and hereditary ATTR.

Symptom type usually tracks to the variant, not just to the mutation itself. V30M in Portugal and Japan tends toward neuropathy. V122I, common in individuals of West African ancestry, tends toward cardiomyopathy. T60A, originally traced to a single family in northwest Ireland, often combines both. A normal life span is genuinely possible with early detection and modern treatment, and the prognosis today differs dramatically from what it looked like twenty years ago.

Knowing a longer healthy interval is likely only helps if relatives actually learn their status, which is where testing and family communication come in.

Genetic Testing, Counseling, and Telling Your Family

Genetic testing for ATTR uses a simple blood or saliva sample that sequences the TTR gene. Most laboratories report results in two to four weeks, and a negative result in someone with confirmed AL or AA amyloidosis confirms that the disease in your family is not hereditary. A positive result means you carry a TTR mutation and can pass it on, even if you feel perfectly well right now.

Who Should Consider Testing

• ▸First-degree relatives of an ATTRv patient: Parents, siblings, and children each face a 50% risk.
• ▸Symptomatic adults with unexplained neuropathy or cardiomyopathy: Especially when combined with bilateral carpal tunnel or a family history suggestive of ATTR.
• ▸Adults with a known TTR mutation in the family: Even without symptoms, baseline cardiac imaging (echocardiogram or bone tracer scintigraphy) often accompanies testing.
• ▸Reproductive-age carriers planning a family: Pre-conception counseling clarifies reproductive options and prenatal testing choices.

What a Genetic Counselor Actually Does

A genetic counselor walks you through the decision before any sample is drawn: what the results may reveal, how the information could affect insurance or employment, and what follow-up steps make sense. Afterward, the counselor interprets the report in plain language, explains what the result does and does not mean for you and your family, and helps you draft a plan for telling relatives. In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits most health insurers and employers from using genetic information against you, though life, disability, and long-term care insurers are not covered.

A Practical Script for Telling Your Family

Keep the first conversation short, factual, and open-ended. A workable opener: “I had genetic testing, and I learned I carry a gene change called [variant] that can run in families. It doesn’t mean everyone in the family will get sick, but it’s worth each adult relative talking with their doctor or a genetic counselor.” Offer to share the lab report, the counselor’s name, and a written summary. Give relatives time, answer questions without pressure, and respect that some will want to act immediately while others will need weeks or months.

Family-Action Checklist

• ▸Gather records: Request the affected relative’s genetic report and pathology results.
• ▸Schedule counseling: Book a session before testing if you want context on what results could mean.
• ▸Get tested or screened: Adults with risk often pair genetic testing with baseline cardiac imaging.
• ▸Share results: Send a short written summary to first-degree relatives and extended family.
• ▸Plan follow-up: Set reminders for repeat screening every 1–3 years, even if you feel well.

Treatments That Have Changed the Outlook for Hereditary ATTR

The treatment landscape for hereditary ATTR has shifted more in the last decade than in the previous fifty years combined. Three classes of therapy now address the underlying biology, and supportive care remains essential for managing symptoms that have already developed.

Stabilizers, Silencers, and Transplant

Tafamidis is a TTR stabilizer that binds the protein in the blood and slows its misfolding into amyloid fibrils. It is approved in the United States for both hereditary ATTR cardiomyopathy and wild-type ATTR cardiomyopathy, and landmark trials showed meaningful reductions in hospitalization and mortality. Gene-silencing therapies, including patisiran, vutrisiran, and inotersen, target the liver to reduce production of mutant TTR, with vutrisiran’s every-three-month subcutaneous dosing making long-term adherence more practical for many carriers. Liver transplantation, once the only meaningful option for selected V30M patients, remains a valid choice for some younger individuals with early-stage disease, sometimes paired with heart transplant when cardiomyopathy dominates the picture.

Alongside these disease-modifying options, supportive care still matters a great deal. Neuropathic pain responds to medications such as duloxetine or gabapentin. Heart failure management relies on careful diuretic use, rate control for arrhythmias, and avoidance of the typical heart-failure drugs that don’t suit stiff ventricles. Nutritional support, mobility aids, and autonomic symptom management round out the day-to-day plan. Patient advocacy organizations such as the Amyloidosis Foundation and research groups such as the Amyloid Research Consortium publish directories of specialty centers where cardiologists, neurologists, and geneticists coordinate care, and the National Amyloidosis Centre in the United Kingdom continues to publish much of the foundational clinical data.

A hereditary diagnosis is no longer the sentence it once was. Early identification, genetic testing for relatives, and modern therapy together have rewritten what living with ATTRv can look like, and your most powerful tool is acting on the information rather than waiting for symptoms to drive the decision.

Those therapies only matter if people reach them in time, so carrying this knowledge forward is the single decision that changes an entire family’s trajectory.

Final Thoughts

When amyloidosis shows up in a family, the single most useful step is naming the type. AL and AA amyloidosis are not inherited. Hereditary ATTR is, with a 50% chance of passing the TTR mutation to each child and a wide spectrum of severity among carriers. Testing, counseling, and early treatment together have turned a once-devastating diagnosis into a manageable one, and the steps you take now ripple outward to every relative who shares that gene.

FAQ